<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01391871</url>
  </required_header>
  <id_info>
    <org_study_id>HAT-TRICK-OCT</org_study_id>
    <nct_id>NCT01391871</nct_id>
  </id_info>
  <brief_title>Vascular Healing of DES at 3 Months</brief_title>
  <acronym>HAT-TRICK-OCT</acronym>
  <official_title>A Randomized Prospective Multicenter Trial to Compare Vascular Healing and Vasodilation at 3 Months After Deployment of PRO-Kinetic Drug-eluting Stent and Endeavor Resolute Zotarolimus-eluting Stent in Patients With Acute Coronary Syndromes by Means of Optical Coherence Tomography and Coronary Flow Reserve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turku</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Hospital District of Satakunta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Turku</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare vascular healing of the stented segment after&#xD;
      deployment of new PRO-Kinetic drug eluting stent and Endeavor Resolute zotarolimus-eluting&#xD;
      stent in patients with acute coronary syndromes requiring percutaneous coronary intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: The aim of the trial is to compare vascular healing and vasodilation at 3 months&#xD;
      after deployment of PRO-Kinetic drug-eluting stent and Endeavor Resolute zotarolimus-eluting&#xD;
      stent in patients with acute coronary syndrome.&#xD;
&#xD;
      Design: A prospective, randomized and controlled study comparing coronary flow reserve and&#xD;
      coverage of the PRO-Kinetic DES and Endeavor Resolute DES implanted in acute coronary&#xD;
      syndrome. OCT and CFR measurement at 3 months. Clinical follow up is scheduled at 3, 6 and 12&#xD;
      months.&#xD;
&#xD;
      Primary endpoint: Uncovered stent struts and CFR at 3 months after stent implantation.&#xD;
&#xD;
      Secondary clinical endpoints: MACE and stent thrombosis.&#xD;
&#xD;
      Enrollment: 40 patients (20 receiving PRO-Kinetic DES and 20 receiving Endeavor Resolute&#xD;
      DES).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Uncovered stent struts</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of uncovered stent struts per stent by OCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Coronary flow reserve</measure>
    <time_frame>3 months</time_frame>
    <description>Coronary flow reserve by transthoracic echocardiography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE and target vessel stent thrombosis</measure>
    <time_frame>12 months</time_frame>
    <description>Death, MI (Q wave or non-Q wave), emergent CABG, or justified TLR by repeat PCI or CABG, and target vessel stent thrombosis.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">46</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>PRO-Kinetic DES</arm_group_label>
    <description>Patients receiving PRO-Kinetic drug-eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endeavor Resolute DES</arm_group_label>
    <description>Patient receiving Endeavor Resolute zotarolimus-eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCT</intervention_name>
    <description>Optical coherence tomography</description>
    <arm_group_label>Endeavor Resolute DES</arm_group_label>
    <arm_group_label>PRO-Kinetic DES</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transthoracic echocardiography CFR measurement</intervention_name>
    <description>CFR will be assessed using transthoracic echocardiography with adenosine infusion.</description>
    <arm_group_label>Endeavor Resolute DES</arm_group_label>
    <arm_group_label>PRO-Kinetic DES</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with acute coronary syndrome treated with PRO-Kinetic DES or Endeavor Resolute DES&#xD;
        during index PCI.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  STEMI or NSTEMI or unstable angina&#xD;
&#xD;
          -  Patient or legally authorized representative has been informed of the nature of the&#xD;
             study, agrees to its provisions and has been provided written informed consent,&#xD;
             approved by the appropriate Medical Ethics committee or Institutional Review Board.&#xD;
&#xD;
          -  Single de novo or non-stented restenosis lesion of LAD&#xD;
&#xD;
          -  Patients with two-vessel disease may have undergone successful treatment of the&#xD;
             non-target vessel with approved devices up to and including the index procedure but&#xD;
             must be treated prior to the index target vessel treatment.&#xD;
&#xD;
          -  Target lesion (maximum 20 mm length by visual estimate) to be covered by a single&#xD;
             stent of maximum 23mm length.&#xD;
&#xD;
          -  Reference vessel diameter must be &gt;2.5mm and &lt;4.0mm by visual estimate.&#xD;
&#xD;
          -  The vessel diameter should be measured after pre-dilation procedure and after&#xD;
             intracoronary nitroglycerin if vasospasm is suspected.&#xD;
&#xD;
          -  Target lesion &gt;50% and &lt;100% stenosed by visual estimate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existing diagnosis of diabetes irrespective of its type.&#xD;
&#xD;
          -  Impaired renal function (serum creatinine &gt;177micromol/l) or on dialysis&#xD;
&#xD;
          -  Platelet count &lt; 10 e5 cells/mm3&#xD;
&#xD;
          -  Patient has a history of bleeding diathesis or coagulopathy or patients in whom&#xD;
             antiplatelet and and/or anticoagulation therapy is contraindicated.&#xD;
&#xD;
          -  Patient has received organ transplant or is on a waiting list for any organ&#xD;
             transplant.&#xD;
&#xD;
          -  Patient has a known hypersensitivity or contraindication to aspirin,&#xD;
             heparin/bivalirudin, clopidogrel/prasugrel, stainless steel alloy, or contrast agent&#xD;
             that cannot be adequately pre-medicated.&#xD;
&#xD;
          -  Patient presents with cardiogenic shock.&#xD;
&#xD;
          -  Any significant medical condition which in the Investigator's opinion may interfere&#xD;
             with the patient's optimal participation in the study.&#xD;
&#xD;
          -  Currently participating in another investigational drug or device study.&#xD;
&#xD;
          -  Unprotected left main disease.&#xD;
&#xD;
          -  Ostial target lesions.&#xD;
&#xD;
          -  Chronic total occlusion.&#xD;
&#xD;
          -  Calcified target lesions that cannot be adequately pre-dilated.&#xD;
&#xD;
          -  Target lesion has excessive tortuosity unsuitable for stent delivery and deployment.&#xD;
&#xD;
          -  Target lesion involving bifurcation with a side branch larger than 2.0mm in diameter.&#xD;
&#xD;
          -  A &gt;30% stenosis proximal or distal to the target lesion that cannot be covered with&#xD;
             the same stent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tuomas Kiviniemi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pasi Karjalainen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Satakunta Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antti Ylitalo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Satakunta Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juhani Airaksinen, MD, PhD, FESC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Satakunta Central Hospital, Pori</name>
      <address>
        <city>Pori</city>
        <zip>28500</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>July 7, 2011</study_first_submitted>
  <study_first_submitted_qc>July 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2011</study_first_posted>
  <last_update_submitted>August 1, 2013</last_update_submitted>
  <last_update_submitted_qc>August 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Turku</investigator_affiliation>
    <investigator_full_name>Tuomas Kiviniemi</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

